Cytokinetics, Incorporated (CYTK) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -891.6%, revenue growth 376.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $88.04M |
| Revenue (TTM) | $0.1B |
| Net Margin | -891.6% |
| Operating Margin (TTM) | -861.2% |
| Net Debt / EBITDA | -0.0 |
| Revenue Growth (YoY) | 376.6% |
| EPS Growth (YoY) | 24.3% |
| FCF Growth (YoY) | 33.8% |
| Price / Sales | 154.28 |
| FCF Yield | -9.4% |
| Altman Z-Score | -1.46 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
CYTK overview · CYTK earnings · CYTK KPIs · CYTK documents · CYTK ownership · CYTK peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.